The European cardiac biomarker market is estimated to grow significantly at a CAGR of around 7.1% during the forecast period. The cardiac biomarker market has a significant scope in the European region due to growing heart related diseases such as CVD, CHD, and stroke. Europe has the highest rates for CVD, CHD and other heart diseases which create a huge demand for diagnosis of cardiac diseases. Europe has a quality healthcare system and adopts the latest cardiology devices and technology to treat heart patients. Europe has a huge economic burden of heart related disease such as CVD, CHD, stroke and other heart diseases. Cardiac biomarkers can be used in the quick diagnosis of cardiac disease. Therefore, the rising incidence of CVD is expected to increase the demand for a cardiac biomarker in the region, which would prevail in the market.
To Request a Sample of our Report on European Cardiac Biomarker Market: https://www.omrglobal.com/request-sample/european-cardiac-biomarker-market
The market is segmented on the basis of type, application, and location of testing. Based on type, the market is segregated into Creatine kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others. The troponin is anticipated to be the fastest growing and has a considerable market share in the European cardiac biomarker market due to easy and high sensitivity that results in the high adoption of the test. Based on Application, the market is segmented into myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. On the basis of the location of testing, the market is classified into laboratory testing and point of care testing.
(Get 15% Discount on Buying this Report)
A full Report of European Cardiac Biomarker Market is Available at: https://www.omrglobal.com/industry-reports/european-cardiac-biomarker-market
European Cardiac Biomarker Market Segmentation
By Type
· Creatine kinase (CK-MB)
· Troponins(T,I)
· Myoglobin
· Natriuretic peptides (BNP & NT-PROBNP)
· Ischemia modified albumin
· Others
By Application
· Myocardial infraction
· Congestive heart failure
· Acute coronary syndrome
· Atherosclerosis
· Others
By Location of Testing
· Laboratory testing
· Point of care testing
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
